Outset Medical, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
OM$4.22+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity
| Convertible Preferred Stock · Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||||
| Balance as of December 31, 2024 | — | $— | 3,530 | $4 | $1,116,496 | $42 | $(1,089,723) | $26,819 | |
| Issuance of Series A convertible preferred stock, net of issuance costs | 863 | 161,071 | — | — | — | — | — | 161,071 | |
| Conversion of convertible preferred stock to common stock | (842) | (157,230) | 14,046 | 14 | 157,216 | — | |||
| Issuance of common stock warrant, net of issuance costs | — | — | — | — | 4,330 | 4,330 | |||
| Issuance of common stock through employee stock purchase plan | — | — | 60 | — | 408 | — | — | 408 | |
| Issuance of common stock for settlement of RSUs | — | — | 86 | — | — | — | — | — | |
| Stock-based compensation expense | — | — | — | — | 2,977 | — | — | 2,977 | |
| Unrealized gain on available-for-sale securities | — | — | — | — | — | 46 | — | 46 | |
| Net loss | — | — | — | — | — | — | (25,783) | (25,783) | |
| Balance as of March 31, 2025 | 21 | $3,841 | 17,722 | $18 | $1,281,427 | $88 | $(1,115,506) | $169,868 | |
| Issuance of common stock for settlement of RSUs | — | — | 44 | — | — | — | — | — | |
| Stock-based compensation expense | — | — | — | — | 3,496 | — | — | 3,496 | |
| Unrealized loss on available-for-sale securities | — | — | — | — | — | (39) | — | (39) | |
| Net loss | — | — | — | — | — | — | (18,541) | (18,541) | |
| Balance as of June 30, 2025 | 21 | $3,841 | 17,766 | $18 | $1,284,923 | $49 | $(1,134,047) | $154,784 | |
Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity
| Convertible Series A Preferred Stock · Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2023 | — | $— | 3,354 | $3 | $1,084,562 | $68 | $(961,747) | $122,886 |
| Issuance of common stock through employee stock purchase plan | — | — | 52 | 1 | 2,079 | — | — | 2,080 |
| Issuance of common stock for settlement of RSUs | — | — | 40 | — | 295 | — | — | 295 |
| Stock option exercises | — | — | — | — | 6 | — | — | 6 |
| Stock-based compensation expense | — | — | — | — | 8,203 | — | — | 8,203 |
| Unrealized loss on available-for-sale securities | — | — | — | — | — | (326) | — | (326) |
| Net loss | — | — | — | — | — | — | (39,944) | (39,944) |
| Balance as of March 31, 2024 | — | $— | 3,446 | $4 | $1,095,145 | $(258) | $(1,001,691) | $93,200 |
| Issuance of common stock for settlement of RSUs | — | — | 21 | — | — | — | — | — |
| Stock option exercises | — | — | 5 | — | 77 | — | — | 77 |
| Stock-based compensation expense | — | — | — | — | 9,820 | — | — | 9,820 |
| Unrealized loss on available-for-sale securities | — | — | — | — | — | (44) | — | (44) |
| Net loss | — | — | — | — | — | — | (34,454) | (34,454) |
| Balance as of June 30, 2024 | — | $— | 3,472 | $4 | $1,105,042 | $(302) | $(1,036,145) | $68,599 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.